Skip to main content

Table 4 Univariable and multivariable analysis of factors associated with 30-day all-cause mortality following VRE bloodstream infection

From: Epidemiology, treatment and outcomes of bloodstream infection due to vancomycin-resistant enterococci in cancer patients in a vanB endemic setting

 Patients who died (n = 27)Patients who survived (n = 66)Univariable odds ratio95% CIp-valueMultivariable odds ratio95% CIp-value
Age, median (IQR), years55 (44–65)58 (43–66)1.000.97–1.030.964   
Male15 (56%)34 (52%)1.180.48–2.890.723   
CDS-VRE, median (IQR)1.9 (1.9–3.9)1.9 (1.5–3.4)1.400.99–1.960.0551.380.96–1.990.082
Haematological malignancy25 (93%)56 (85%)2.230.46–10.940.322   
AlloBMT9 (33%)15 (23%)1.700.63–4.560.291   
Hypoalbuminemia days, median (IQR)22 (11–30)16 (10–23)1.051.00–1.100.0581.040.98–1.090.186
Mucositis grade, median (IQR)0 (0–3)0 (0–2)1.150.86–1.540.336   
Polymicrobial BSI7 (26%)14 (21%)1.300.46–3.690.622   
Neutropenia at time of BSI20 (74%)55 (83%)0.570.20–1.680.308   
Teicoplanin monotherapy14 (52%)45 (68%)0.540.22–1.380.2000.570.20–1.640.299
ICU 48 h after BSI8 (30%)5 (8%)5.141.50–17.580.0094.161.08–16.000.038
  1. CDS-VRE score Chronic Disease Score specific to VRE, CKD Chronic kidney disease, AML Acute myeloid leukaemia, alloBMT allogeneic bone marrow transplant, BSI Blood stream infection
  2. In 30 days prior to bloodstream infection